The Fort Worth Press - Inspire Veterinary Partners Reports Second Quarter 2025 Financial Results

USD -
AED 3.6725
AFN 63.499288
ALL 81.244999
AMD 376.110854
ANG 1.789731
AOA 917.000113
ARS 1399.250556
AUD 1.414377
AWG 1.8
AZN 1.697579
BAM 1.647475
BBD 2.012046
BDT 122.174957
BGN 1.647646
BHD 0.3751
BIF 2946.973845
BMD 1
BND 1.262688
BOB 6.903087
BRL 5.219398
BSD 0.998947
BTN 90.484774
BWP 13.175252
BYN 2.862991
BYR 19600
BZD 2.009097
CAD 1.36113
CDF 2255.000065
CHF 0.769502
CLF 0.021854
CLP 862.95954
CNY 6.90865
CNH 6.902365
COP 3660.44729
CRC 484.521754
CUC 1
CUP 26.5
CVE 92.882113
CZK 20.429601
DJF 177.88822
DKK 6.29223
DOP 62.233079
DZD 128.996336
EGP 46.602105
ERN 15
ETB 155.576128
EUR 0.84232
FJD 2.19355
FKP 0.732487
GBP 0.732869
GEL 2.675024
GGP 0.732487
GHS 10.993556
GIP 0.732487
GMD 73.49862
GNF 8768.057954
GTQ 7.662048
GYD 208.996336
HKD 7.81659
HNL 26.394306
HRK 6.348601
HTG 130.985975
HUF 319.275502
IDR 16832.8
ILS 3.09073
IMP 0.732487
INR 90.560979
IQD 1308.680453
IRR 42125.000158
ISK 122.169801
JEP 0.732487
JMD 156.340816
JOD 0.709001
JPY 152.65007
KES 128.812703
KGS 87.449835
KHR 4018.026366
KMF 415.000021
KPW 900.035341
KRW 1440.859901
KWD 0.30661
KYD 0.832498
KZT 494.35202
LAK 21437.897486
LBP 89457.103146
LKR 308.891042
LRD 186.25279
LSL 16.033104
LTL 2.95274
LVL 0.60489
LYD 6.298277
MAD 9.134566
MDL 16.962473
MGA 4370.130144
MKD 51.922672
MMK 2099.386751
MNT 3566.581342
MOP 8.044813
MRU 39.81384
MUR 45.923681
MVR 15.405025
MWK 1732.215811
MXN 17.167502
MYR 3.907504
MZN 63.910395
NAD 16.033104
NGN 1353.401883
NIO 36.760308
NOK 9.52676
NPR 144.775302
NZD 1.658379
OMR 0.38258
PAB 0.999031
PEN 3.351556
PGK 4.288422
PHP 57.848497
PKR 279.396706
PLN 3.54658
PYG 6551.825801
QAR 3.640736
RON 4.291401
RSD 98.909152
RUB 77.162105
RWF 1458.450912
SAR 3.749258
SBD 8.045182
SCR 13.47513
SDG 601.502867
SEK 8.925225
SGD 1.26352
SHP 0.750259
SLE 24.450031
SLL 20969.49935
SOS 570.441814
SRD 37.754041
STD 20697.981008
STN 20.637662
SVC 8.741103
SYP 11059.574895
SZL 16.029988
THB 31.080376
TJS 9.425178
TMT 3.5
TND 2.880259
TOP 2.40776
TRY 43.608497
TTD 6.780946
TWD 31.383954
TZS 2607.252664
UAH 43.08175
UGX 3536.200143
UYU 38.512404
UZS 12277.302784
VES 392.73007
VND 25970
VUV 119.056861
WST 2.712216
XAF 552.547698
XAG 0.012937
XAU 0.000198
XCD 2.70255
XCG 1.800362
XDR 0.687192
XOF 552.547698
XPF 100.459083
YER 238.350419
ZAR 15.950056
ZMK 9001.200634
ZMW 18.156088
ZWL 321.999592
  • RBGPF

    0.1000

    82.5

    +0.12%

  • CMSD

    0.0647

    23.64

    +0.27%

  • GSK

    0.3900

    58.93

    +0.66%

  • RELX

    2.2500

    31.06

    +7.24%

  • CMSC

    0.0500

    23.75

    +0.21%

  • BCE

    -0.1200

    25.71

    -0.47%

  • BTI

    -1.1100

    59.5

    -1.87%

  • AZN

    1.0300

    205.55

    +0.5%

  • BCC

    -1.5600

    86.5

    -1.8%

  • NGG

    1.1800

    92.4

    +1.28%

  • RIO

    0.1600

    98.07

    +0.16%

  • RYCEF

    0.2300

    17.1

    +1.35%

  • JRI

    0.2135

    13.24

    +1.61%

  • BP

    0.4700

    37.66

    +1.25%

  • VOD

    -0.0500

    15.57

    -0.32%

Inspire Veterinary Partners Reports Second Quarter 2025 Financial Results
Inspire Veterinary Partners Reports Second Quarter 2025 Financial Results

Inspire Veterinary Partners Reports Second Quarter 2025 Financial Results

Comparable clinic revenues increase 5.7% vs prior year period

Net losses decrease 10% vs. prior year period

Text size:

VIRGINIA BEACH, VA / ACCESS Newswire / August 14, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) ("Inspire" or the "Company"), an owner and provider of pet health care services throughout the U.S., today reported financial results for the second quarter ended June 30, 2025.

Second Quarter 2025 Financial Highlights Compared to Prior Periods

  • Total revenue of approximately $4.3 million, a sequential increase of 20% from Q1 2025 and a decrease of 2% from the prior year period. The decrease in revenue is attributed to the exclusion of the Hawaii clinic (KVC) from 2025 results

  • Services revenue of approximately $3.2 million, a sequential increase of 17% from Q1 2025 and a decrease of 1% from the prior year period

  • Product revenue of $1.1 million, a sequential increase of 21% from Q1 2025 and a decrease of 7% from the prior year period

  • Comparable clinic revenues increased 5.7% from the prior year period

  • Total operating expenses of $6.2 million, an increase of 5% from the prior year period

  • Net loss of $3.0 million, a decrease of $0.4 million from the prior year period

  • Entered an exclusive, non-binding Letter of Intent to acquire 100% ownership interest in one animal hospital located in New Jersey. Once completed, the acquisition could potentially add up to approximately $2.0 million in (unaudited) revenue

  • Entered into a securities purchase agreement for the issuance and sale of securities for up to $10M under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share

  • Announced the launch of a company-wide incentive and recognition program, which provides vital new engagement tools and offers new avenues to wealth for all employees across their clinic network

  • Integrated a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into the Company's medical software. The Company believes this is the only AI platform being offered among publicly traded veterinary clinic networks

  • Acquired 100% ownership interest in one animal hospital located in central Florida (DeBary). The acquisition is expected to add up to approximately $1.8 million in (unaudited) revenue, and brings the Company's Florida holdings up to 5 clinics

  • For the second quarter of 2025, total revenue was approximately $4.3 million, a decrease of 2% from the prior year period but an increase of 20% from Q1 2025. Comparable clinic revenues increased 5.7% from the prior year period.

Second Quarter 2025 Operational Highlights

  • Entered an exclusive, non-binding Letter of Intent to acquire 100% ownership interest in one animal hospital located in New Jersey. Once completed, the acquisition could potentially add up to approximately $2.0 million in (unaudited) revenue

  • Entered into a securities purchase agreement for the issuance and sale of securities for up to $10M under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share

  • Announced the launch of a company-wide incentive and recognition program, which provides vital new engagement tools and offers new avenues to wealth for all employees across their clinic network

  • Integrated a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into the Company's medical software. The Company believes this is the only AI platform being offered among publicly traded veterinary clinic networks

  • Acquired 100% ownership interest in one animal hospital located in central Florida (DeBary). The acquisition is expected to add up to approximately $1.8 million in (unaudited) revenue, and brings the Company's Florida holdings up to 5 clinics

Executive Commentary

"During the second quarter of 2025, we started to see the rewards of our new initiatives, processes, and hard work over the past 18 months with sequential revenue growth of 20% and year over year organic growth of 5.7%.," said Kimball Carr, Inspire 's Chairman, President and Chief Executive Officer. "We also grew our portfolio of clinics to 14 with the recently announced acquisition in Florida while significantly improving our liquidity and capital structure with the recently announced preferred stock transaction. I believe this quarter will mark the turning point for our business model and that our top line growth will accelerate going forward.

Second Quarter 2025 Financial Overview

All comparisons are made relative to the same period in 2024 unless otherwise stated.

  • For the second quarter of 2025, total revenue was approximately $4.3 million, a decrease of 2% from the prior year period but an increase of 20% from Q1 2025. Comparable clinic revenues increased 5.7% from the prior year period.

  • Service revenue for the second quarter of 2025 decreased $25,000 or 1%, to $3.2 million. The decrease in service revenue is mainly attributed to the exclusion of KVC from 2025 results and reduced practitioner capacity. These decreases were partially offset by the acquisition of the DeBary animal clinic during Q2 2025.

  • Product revenue for the second quarter 2025 decreased $82,000, or 7%, to $1.1 million. The overall decrease was a result of customers purchasing less products per visit and the exclusion of KVC from 2025 results partially offset by the acquisition of the DeBary animal clinic during Q2 2025.

  • Total operating expenses increased $285,000 or 5%. The increase is primarily due to increased costs of consulting agreements relating to customer outreach and public company costs.

  • Net loss for the first quarter of 2025 decreased $352,000, or 10%, to $3.0 million. The decline in net loss is primarily attributable to the reduction of interest expense and the exclusion of the operating expenses associated with KVC.

Balance Sheet

As of June 30, 2025, the Company had cash and cash equivalents of approximately $0.2 million.

About Inspire Veterinary Partners, Inc.

Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.

For more information, please visit: www.inspirevet.com.

Connect with Inspire Veterinary Partners, Inc.

Facebook

https://www.facebook.com/InspireVeterinaryPartners/

LinkedIn

https://www.linkedin.com/company/inspire-veterinary-partners/

Forward-Looking Statements

This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding management's expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption "Risk Factors" in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Investors
CoreIR
516-386-0430

General Inquiries
Morgan Wood
[email protected]

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Balance Sheet

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Operation

Inspire Veterinary Partners, Inc. and Subsidiaries
Consolidated Statements of Cash Flows

SOURCE: INSPIRE VETERINARY PARTNERS, INC.



View the original press release on ACCESS Newswire

J.P.Cortez--TFWP